Effects of fasting, refeeding, and fasting with T3 administration on Na-K,ATPase in rat skeletal muscle.
It is known that Na-K,adenosine triphosphatase (ATPase) in cell membranes represents an important consumer of cellular energy, eg, adenosine triphosphate (ATP), and that the concentration and activity of this enzyme change in a dose-dependent manner with serum thyroid hormone levels. To examine the hypothesis that low triiodothyronine (T3) syndrome represents a cellular adaptation in generalized severe illnesses that saves tissue energy expenditure, we measured the muscle Na-K,ATPase concentration and its activity in rats that led to low T3 syndrome induced by fasting. The Na-K,ATPase concentration was measured by 3H-ouabain binding to soleus muscle, and its activity was measured by 42K uptake in the contralateral soleus muscle. The effects of refeeding or T3 administration on Na-K,ATPase in soleus muscle in fasted rats were also examined. Na-K,ATPase concentration and activity were both increased in hyperthyroid rats and decreased in hypothyroid rats. In the fasting state, they were decreased to as low as the levels seen in hypothyroidism. Furthermore, with fasting + refeeding or fasting + T3 administration, Na-K,ATPase in soleus muscle returned to the normal level. These results suggest that tissue energy expenditure, as assessed by Na-K,ATPase, in skeletal muscles of fasted rats with low T3 syndrome is actually decreased to levels seen in hypothyroidism, due at least partly to the decrease in serum T3 concentrations, and that there exist some adaptation mechanisms in the peripheral tissues for the accommodation of energy metabolism in the body through decreased thyroxine (T4) to T3 conversion.
Matsumura
M
M
Division of Endocrinology and Metabolism, University of Tsukuba, Japan.
Kuzuya
N
N
Kawakami
Y
Y
Yamashita
K
K
D000255:Adenosine Triphosphate / Q000032:analysis; D000818:Animals; D001692:Biological Transport / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D004435:Eating / Q000502:physiology*; D005215:Fasting / Q000502:physiology*; D006980:Hyperthyroidism / Q000097:blood / Q000201:enzymology / Q000503:physiopathology; D007037:Hypothyroidism / Q000097:blood / Q000201:enzymology / Q000503:physiopathology; D007274:Injections, Intraperitoneal; D007527:Isoenzymes / Q000378:metabolism*; D008297:Male; D009132:Muscles / Q000187:drug effects / Q000201:enzymology* / Q000502:physiology; D010042:Ouabain; D011197:Potassium Radioisotopes / Q000493:pharmacokinetics; D051381:Rats; D011919:Rats, Inbred Strains; D000254:Sodium-Potassium-Exchanging ATPase / Q000378:metabolism*; D014284:Triiodothyronine / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*; D014316:Tritium
D007527:Isoenzymes; D011197:Potassium Radioisotopes; D014284:Triiodothyronine; D014316:Tritium; D010042:Ouabain; D000255:Adenosine Triphosphate; D000254:Sodium-Potassium-Exchanging ATPase